AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04375306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guided CABG
Description: All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
Study NCT01188850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
Study NCT01370317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Study NCT01115192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
Study NCT02228616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
Study NCT00005973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV
Study NCT02228616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Description: Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
Study NCT02228616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
Study NCT01149954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study NCT01149954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study NCT00303589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: As prescribed
Study NCT00303589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 750mg iv q8h
Study NCT00303589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 1500mg iv q8h
Study NCT03670420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical honey
Description: The investigators use Medihoney®, a medical honey released by the DermaSciences.
Study NCT04469829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: standard doses of secukinumab for psoriasis
Study NCT04469829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15 mg/week
Study NCT01568528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
Study NCT01568528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
Study NCT01568528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
Study NCT01849887 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow-derived mesenchymal stem cells
Description: bone marrow-derived mesenchymal stem cells
Study NCT01849887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03454009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal hygiene intervention
Description: hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
Study NCT00005973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03364439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment plan
Description: R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
Study NCT03176017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ejaculatory sparing TUIP
Description: The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
Study NCT03176017 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional TUIP
Description: the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
Study NCT03526380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: the OPT-IN Intervention
Description: A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
Study NCT03355482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 160mg IM at baseline
Study NCT03355482 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebos
Description: IM saline injection at baseline
Study NCT03720314 — intervention group
Intervention type: OTHER
Intervention: NA observational study
Description: observational study
Study NCT00472693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Abraxane
Description: Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
Study NCT02075801 — intervention group
Intervention type: OTHER
Intervention: Sealing of amalgam margin defects
Description: Comparison between sealing of amalgam margins defects, replacement and non treated groups.
Study NCT02075801 — intervention group
Intervention type: OTHER
Intervention: Sealing of amalgam margin defects
Description: A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment.
Study NCT03209401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: an oral PARP inhibitor
Study NCT01223443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent
Description: Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
Study NCT01579812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy.
Study NCT02612831 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early bariatric surgery
Study NCT03209401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: a platinum-based injection
Study NCT01370317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-1029
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Study NCT05258474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)
Description: single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
Study NCT02692625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (L. reuteri Prodentis®).
Description: The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
Study NCT02612831 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed bariatric surgery
Study NCT01138176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Reduction of rectal temperature to 33.5 C
Study NCT01138176 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Cooling
Description: Reduction of rectal temperature to 33.5 C
Study NCT03452449 — intervention group
Intervention type: PROCEDURE
Intervention: planned lumbar spine surgery
Description: planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
Study NCT01970904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
Study NCT01970904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets of various strengths for oral administration
Study NCT01970904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a solution for subcutaneous injection
Study NCT03381534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting with EPD
Description: participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
Study NCT03381534 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: stent assisted angioplasty
Description: participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
Study NCT02692625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
Study NCT03691740 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ocular light
Description: A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
Study NCT03691740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular light
Description: A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
Study NCT04187287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave Therapy
Description: Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
Study NCT04187287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Friction Massage
Description: Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
Study NCT00493857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Humanized Monoclonal Antibody
Description: Nimotuzumab 400mg every week
Study NCT00493857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400mg every 2 weeks
Study NCT00686634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg by mouth once daily
Study NCT04095637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial knee arthroplasty
Description: Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
Study NCT04095637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medial knee arthroplasty
Description: Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
Study NCT00906438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2006-RD-05
Description: 300 mg daily, once a day for 28 consecutive days
Study NCT00906438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
Study NCT00734955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 49-channel optical spectrometer
Study NCT01214057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Remifentanyl
Description: Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
Study NCT01214057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and Remifentanyl
Description: Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
Study NCT00880464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Lethally Irradiated Breast Cancer Cells
Description: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
Study NCT00729391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Woman-Focused Intervention (Women's Health CoOp)
Description: Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
Study NCT00729391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition (Attention-Control)
Description: Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
Study NCT00729391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VCT Only
Description: Participants in this group will receive VCT only.
Study NCT01743001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Macitentan 10 mg oral tablet once daily
Study NCT01743001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Macitentan-matching placebo oral tablet once daily
Study NCT02470637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR439065
Description: Pharmaceutical form:dry powder insulin~Route of administration: inhalation
Study NCT02470637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT01515020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin monotherapy
Description: intravenous therapy by vancomycin
Study NCT01515020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin monotherapy
Description: intravenous therapy by daptomycin
Study NCT05258474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release nicotinamide (SAD)
Description: single-ascending dose (SAD)
Study NCT05258474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)
Description: single- and multiple-ascending dose (SAD/MAD)
Study NCT05258474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Immediate-release nicotinamide (SAD)
Description: single-ascending dose (SAD)
Study NCT00400296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG547
Description: Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
Study NCT05088239 — intervention group
Intervention type: DRUG
Intervention: prophylactic antibiotics duration
Description: Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
Study NCT01692821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100% oxygen breathing
Description: 100% oxygen breathing - 30 minutes
Study NCT01692821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% oxygen in N2 breathing
Description: 15% oxygen in N2 breathing - 30 minutes
Study NCT01692821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12% oxygen in N2 breathing
Description: 12% oxygen in N2 breathing - 30 minutes
Study NCT02251548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral BTK inhibitor
Study NCT02251548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV purine analogue chemotherapy agent
Study NCT02251548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV alkylator chemotherapy agent
Study NCT02251548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV anti-CD20 monoclonal antibody
Study NCT02296138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination
Study NCT02296138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination
Study NCT02296138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study NCT01781091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION
Study NCT01781091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionals Modes
Study NCT01322776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Bortezomib, Fludarabine and Cyclophosphamide
Description: bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
Study NCT04050020 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Description: All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
Study NCT04050020 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.